Owkin is an AI biotech founded in Paris that uses machine learning on medical data to accelerate drug discovery, clinical trials and diagnostics.
Owkin builds AI models that learn from distributed hospital and research data without moving it — a federated approach that respects patient privacy while unlocking predictive insights. Its platform supports target discovery, clinical trial optimization and digital pathology, and the company partners with pharmaceutical firms and hospitals to bring AI into medical research. Owkin also develops diagnostic tools and has built a network of academic hospital partnerships across Europe and the US.
Owkin works through research partnerships and enterprise agreements with pharma and healthcare organizations; commercial terms are project-specific.
Pharmaceutical R&D teams, hospitals and medical researchers who want AI insights from sensitive data without compromising privacy.
Owkin serves medical research where patient data cannot move but insight must.
Partnerships begin with a scientific discussion: align on a research question, connect data through Owkin’s federated infrastructure and run studies together.
Researchers gain models trained on broader data than any single institution holds, while privacy and regulatory obligations remain intact.
Partnerships begin with a scientific question and data governance design; Owkin’s federated infrastructure then runs studies across institutions with ongoing research support.
Federated setups demand institutional commitment and time, and results depend on data harmonization across partners.
Researchers value accessing broader data without compromising patient privacy or legal obligations.
Owkin’s federated approach answers the question that stalls most medical AI: how to learn from data that cannot move. For pharma and hospitals willing to invest in partnerships, it unlocks research breadth without privacy compromise — patience required, but the alternative is years of data-legal deadlock.
No. Owkin engages through research collaborations and commercial partnerships rather than self-serve products.
Access is delivered through partnership platforms and federated infrastructure designed with each institution.
Against general medical-AI vendors, Owkin’s federated approach lets models learn from multiple institutions’ data lawfully — a decisive edge in research settings.